Home/Pipeline/Wynzora

Wynzora

Plaque Psoriasis

MarketedCommercial GrowthNCT03308744

Key Facts

Indication
Plaque Psoriasis
Phase
Marketed
Status
Commercial Growth
Company

About Almirall

Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.

View full company profile

Other Plaque Psoriasis Drugs

DrugCompanyPhase
Piclidenoson (CF101)Can Fite BiopharmaPhase III
Psoriasis TrialClinical Investigation SpecialistsNot Specified
ZL-1102 (CB001)Crescendo BiologicsPhase 2
AX-158Artax BiopharmaPhase 2
JNJ-2113Johnson & JohnsonPhase 3
VTAMA® (tapinarof)Roivant SciencesApproved
JNJ-81201887 (via Janssen)OmniAbApproved